Faro AI

Name: Faro AI
Brand: Faro

Transforming Clinical Development with the Power of AI

Est 2018|8 Ref Customers

LinkedIn 12K|Website|Web traffic 3K|FTEs 4|HQ Miami, FL

Published Oct 15, 2026

01Common complaints

- Company sizes or stages where this product is overkill or insufficient - Early-stage biotech with a single near-term trial may not recover implementation and change-management costs. - Industries or use cases where competitors are clearly superior - If an organization needs a fully integrated EDC/CTMS/regulatory suite rather than a protocol-design-focused system, larger platform vendors may be a better strategic fit. - If an organization is standardized on a specific platform (for example, Medidata Rave) and requires immediate, tightly integrated build acceleration within that ecosystem, a native solution may be preferable. - Technical requirements that this product cannot meet - If procurement requires publicly verifiable, downloadable security reports, explicit subprocessor lists, or documented data residency options and the vendor provides only gated materials, this may be a procurement blocker. - Budget constraints that make alternatives more appropriate - Organizations that require transparent, low-cost, per-seat pricing may find an enterprise quote model a mismatch. - Specific workflows or integrations where the product falls short - Highly customized downstream systems may require manual exception handling and validation even if the vendor offers automated build features. - Red flags in the buying process - ROI presented as modeled or potential savings without an agreed-upon measurement methodology and baselining; heavy dependence on vendor professional services to achieve outcomes. - Current limitations acknowledged by the vendor - The vendor's public pages do not include an explicit limitations section; marketing pages emphasize capabilities. - Features on the roadmap (not yet available) - Vendor insight posts indicate ongoing expansion toward additional downstream workflow connectivity and more automated features; roadmap items and delivery dates are not concretely committed in the public materials reviewed. - Scale limitations (at what volume/size does it break down?) - Not publicly documented. - Security or compliance gaps - While SOC 2 Type II and ISO 27001:2022 are asserted by the vendor, details such as hosting regions, explicit data residency options, SCIM provisioning, and publicly downloadable audit reports are not fully documented on the captured Trust Center page. - Technical debt or architectural limitations mentioned in reviews - Not found due to limited independent review availability. - API limitations or integration constraints - Not publicly documented in the sources captured.

Deal disqualifiers: what makes a POOR fit

Teams requiring a purely self-serve, low-cost tool with transparent public pricing; organizations unwilling to change Word-first authoring processes; very small sponsors with infrequent trials.

Why some customers left for competitors (churn reasons)

No credible, directly attributable churn narratives were found in public sources for the clinical-development Faro during this research.

02Why they buy

- Competitive advantages validated by customer feedback (not just vendor claims) - Public, user-generated feedback specific to this vendor is limited in accessible review platforms; therefore validation relies more on published methodology papers and independent editorial narratives than on broad peer reviews. - Unique features and capabilities competitors lack (as positioned) - Vendor positioning emphasizes capturing protocol and study design as structured data from inception, providing a substrate for analytics and generative-AI-assisted authoring rather than applying AI to unstructured documents. - Differentiation from competitors based on reviews - Not possible to substantiate through major review platforms in this research due to limited attributable listings for the clinical-development vendor. - Value propositions with evidence from case studies - A published methodological example demonstrates quantified schedule-of-assessment simplification using the vendor's tooling in a workshop context; the example includes vendor participation and reports modeled outcomes. - Areas where competitors clearly have advantages (balanced view) - Suite coherence and installed base: larger incumbents may provide broader coverage across EDC, regulatory submissions, and content management, which can reduce integration friction. - Review footprint: established vendors often have more third-party reviews and analyst coverage, which aids reference validation.

Why customers chose this product over alternatives (evidence available)

Independent editorial coverage and interviews describe the vendor's emphasis on capturing protocols as structured data early, which can enable analytics and improve the quality of generative-AI-assisted authoring compared with applying models to unstructured Word documents.

03Field reports

Important context: review data availability and name ambiguity

The vendor name "Faro" overlaps with other unrelated products and companies. Search results on major review platforms sometimes return entries for other firms (for example, engineering-productivity vendors and metrology companies). This creates a high risk of misattribution in public review searches.

Review platform findings

- Gartner Peer Insights: public search results surfaced entries for other vendors with similar names; no clearly attributable Gartner Peer Insights reviews for the clinical-development Faro were identified in accessible results. - G2: search results also surfaced listings for other similarly named vendors rather than the clinical-development Faro; no clearly attributable G2 listing/reviews were found for this vendor in the results reviewed. - TrustRadius / Capterra: no clearly attributable pages for the clinical-development Faro were found during this research.

Community / social proof (relevant + irrelevant)

Relevant discussion: a regulatory/clinical writing forum thread discusses a publication and methods related to schedule-of-assessments simplification; that thread concerns methodology rather than direct product usage reviews.
Irrelevant results: many public search results for "Faro" refer to unrelated entities (for example, individuals or other companies) and were excluded.

Vendor testimonials and ROI claims (treated as vendor-published unless independently validated)

- The vendor publishes modeled outcomes such as projected cost and burden reductions (e.g., modeled savings and participant-burden reductions). Independent corroboration of realized outcomes across multiple customers was not available in public sources. - A related preprint and publication describe use of a Faro-affiliated tool and workshops in protocol redesign exercises; those materials provide methodological context but include vendor participation and are not independent audits of realized enterprise-wide ROI.

Specific outcomes customers achieved (with metrics when available)

The referenced publication/preprint documents quantified impacts in specific protocol redesign exercises involving vendor personnel; these are scoped to discrete exercises and include vendor involvement, so they should be interpreted as limited-scope examples rather than generalized, independently verified outcomes.

Deal-breakers and reasons customers didn't purchase

No public "lost deal" testimonials were identified for this vendor in the sources reviewed.

Published methodology example (Merck protocols / schedule-of-assessments redesign)

- A preprint describes use of a vendor-affiliated tool and workshop-based redesign sessions to quantify hours, burden, cost, and complexity. The case documents a repeatable methodology for assessing and simplifying schedules of assessments. - Critical evaluation - Strengths - The work product is more concrete than typical marketing claims because it describes quantification of burden, time, cost, and complexity and situates these in a repeatable workshop process. - Limitations - Vendor involvement in the workshops introduces potential bias. The results are scoped to specific exercises and are reported as modeled or potential savings rather than independently audited, realized outcomes.

Other claims and examples

Vendor blog posts and interviews describe reductions in authoring cycle time in selective examples; these are vendor-published narratives and should be treated as illustrative rather than independently validated.

04Best fit

Company sizes: specific employee counts and revenue ranges (hypothesis)

Best-fit hypothesis based on vendor messaging and product category:
- Large biopharma and mid-to-large biotech sponsors with multiple concurrent programs where protocol reuse and amendment reduction can yield material savings.
- Plausible ranges: mid-sized to very large organizations across a broad revenue band.

Industries and verticals where adoption is strongest

Sponsor-side clinical development teams in biopharma and biotech.

Roles and personas: decision makers AND end users

Decision makers: heads of clinical operations, clinical development leadership, heads of data management or clinical informatics, procurement, and quality/compliance leadership.
End users: clinical scientists (protocol design), medical writers (protocol authoring), and study startup/build teams responsible for EDC build and specifications.

Pain points and challenges the product addresses

Reducing translation overhead between protocol documents and operational systems; shortening authoring cycles and review loops; quantifying participant and site burden and operational complexity.

Qualification criteria: what makes a GREAT fit

Organizations willing to adopt structured protocol design as a core process; high protocol volume or frequent amendments; desire to connect design decisions to downstream automation.

Real customer examples with company names when available

Public materials reference collaborations in methodological publications and editorial coverage with major pharmaceutical involvement, but public materials do not demonstrate broad, production-wide deployment across named customers.

05The pitch

What the product does (core value proposition in objective terms)

- Faro is a platform that applies artificial intelligence and analytics to clinical protocol and study design, protocol document authoring, and workflow automation, including capabilities for generating structured study definitions and helping seed downstream systems such as EDCs. - Core workflow premise: convert protocols from static documents into structured digital study definitions, then apply analytics and generative AI to inform protocol content and support downstream study build activities (for example, EDC configuration).

Target market and market positioning

- Primary customers are biopharmaceutical clinical development organizations (sponsors) and study teams involved in protocol design, medical writing, and study startup and execution. Vendor materials reference engagements with large pharmaceutical customers. - Category framing (plain terms) - Digital protocol / study design system - Protocol authoring acceleration using generative AI for medical writing - Study build automation and digital data flow into downstream systems

Get a comprehensive analysis of Faro AI including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →